vs

Side-by-side financial comparison of PUMA BIOTECHNOLOGY, INC. (PBYI) and UNITED STATES LIME & MINERALS INC (USLM). Click either name above to swap in a different company.

UNITED STATES LIME & MINERALS INC is the larger business by last-quarter revenue ($87.9M vs $75.5M, roughly 1.2× PUMA BIOTECHNOLOGY, INC.). On growth, PUMA BIOTECHNOLOGY, INC. posted the faster year-over-year revenue change (27.7% vs 9.8%). UNITED STATES LIME & MINERALS INC produced more free cash flow last quarter ($25.7M vs $14.4M). Over the past eight quarters, PUMA BIOTECHNOLOGY, INC.'s revenue compounded faster (31.3% CAGR vs 10.8%).

Puma Biotechnology is a publicly traded biopharmaceutical company headquartered in Los Angeles, CA.

United States Lime & Minerals Inc is a leading US-based natural resources enterprise that produces high-calcium lime, dolomitic lime, limestone and related mineral products. Its core client segments cover infrastructure construction, steel manufacturing, agricultural soil amendment, environmental emission control and industrial processing, serving customers across North America.

PBYI vs USLM — Head-to-Head

Bigger by revenue
USLM
USLM
1.2× larger
USLM
$87.9M
$75.5M
PBYI
Growing faster (revenue YoY)
PBYI
PBYI
+17.9% gap
PBYI
27.7%
9.8%
USLM
More free cash flow
USLM
USLM
$11.3M more FCF
USLM
$25.7M
$14.4M
PBYI
Faster 2-yr revenue CAGR
PBYI
PBYI
Annualised
PBYI
31.3%
10.8%
USLM

Income Statement — Q4 FY2025 vs Q4 FY2025

Metric
PBYI
PBYI
USLM
USLM
Revenue
$75.5M
$87.9M
Net Profit
$30.5M
Gross Margin
69.3%
48.0%
Operating Margin
22.7%
41.0%
Net Margin
34.7%
Revenue YoY
27.7%
9.8%
Net Profit YoY
13.2%
EPS (diluted)
$0.26
$1.06

Green = leading value per metric. Periods may differ when fiscal calendars don't align.

8-Quarter Revenue & Profit Trend

Side-by-side quarterly history. Quarters aligned by calendar period so offset fiscal years line up.

Revenue
PBYI
PBYI
USLM
USLM
Q4 25
$75.5M
$87.9M
Q3 25
$54.5M
$102.0M
Q2 25
$52.4M
$91.5M
Q1 25
$46.0M
$91.3M
Q4 24
$59.1M
$80.1M
Q3 24
$80.5M
$89.4M
Q2 24
$47.1M
$76.5M
Q1 24
$43.8M
$71.7M
Net Profit
PBYI
PBYI
USLM
USLM
Q4 25
$30.5M
Q3 25
$8.8M
$38.8M
Q2 25
$5.9M
$30.8M
Q1 25
$3.0M
$34.1M
Q4 24
$27.0M
Q3 24
$20.3M
$33.4M
Q2 24
$-4.5M
$26.1M
Q1 24
$-4.8M
$22.4M
Gross Margin
PBYI
PBYI
USLM
USLM
Q4 25
69.3%
48.0%
Q3 25
77.7%
51.2%
Q2 25
76.5%
45.8%
Q1 25
77.1%
50.6%
Q4 24
76.4%
44.3%
Q3 24
63.9%
48.2%
Q2 24
77.4%
45.5%
Q1 24
75.5%
42.7%
Operating Margin
PBYI
PBYI
USLM
USLM
Q4 25
22.7%
41.0%
Q3 25
17.6%
45.3%
Q2 25
12.7%
39.0%
Q1 25
8.7%
43.7%
Q4 24
22.6%
38.8%
Q3 24
27.4%
42.6%
Q2 24
-4.6%
39.1%
Q1 24
-5.3%
35.9%
Net Margin
PBYI
PBYI
USLM
USLM
Q4 25
34.7%
Q3 25
16.2%
38.0%
Q2 25
11.2%
33.7%
Q1 25
6.5%
37.4%
Q4 24
33.7%
Q3 24
25.2%
37.3%
Q2 24
-9.6%
34.0%
Q1 24
-11.0%
31.3%
EPS (diluted)
PBYI
PBYI
USLM
USLM
Q4 25
$0.26
$1.06
Q3 25
$0.17
$1.35
Q2 25
$0.12
$1.07
Q1 25
$0.06
$1.19
Q4 24
$0.40
$-2.20
Q3 24
$0.41
$1.16
Q2 24
$-0.09
$0.91
Q1 24
$-0.10
$3.92

Balance Sheet & Financial Strength

Snapshot of each company's liquidity, leverage and book value from the latest quarter.

Metric
PBYI
PBYI
USLM
USLM
Cash + ST InvestmentsLiquidity on hand
$97.5M
$371.1M
Total DebtLower is stronger
$22.7M
$0
Stockholders' EquityBook value
$130.3M
$630.8M
Total Assets
$216.3M
$681.0M
Debt / EquityLower = less leverage
0.17×
0.00×

8-quarter trend — quarters aligned by calendar period.

Cash + ST Investments
PBYI
PBYI
USLM
USLM
Q4 25
$97.5M
$371.1M
Q3 25
$94.4M
$349.5M
Q2 25
$96.0M
$319.9M
Q1 25
$93.2M
$300.6M
Q4 24
$101.0M
$278.0M
Q3 24
$96.7M
$255.0M
Q2 24
$96.8M
$222.5M
Q1 24
$107.2M
$207.0M
Total Debt
PBYI
PBYI
USLM
USLM
Q4 25
$22.7M
$0
Q3 25
$34.0M
$0
Q2 25
$45.3M
$0
Q1 25
$56.7M
$0
Q4 24
$68.0M
$0
Q3 24
$79.3M
$0
Q2 24
$90.7M
$0
Q1 24
$102.0M
$0
Stockholders' Equity
PBYI
PBYI
USLM
USLM
Q4 25
$130.3M
$630.8M
Q3 25
$115.3M
$602.3M
Q2 25
$104.7M
$563.3M
Q1 25
$97.1M
$532.2M
Q4 24
$92.1M
$497.7M
Q3 24
$71.1M
$474.2M
Q2 24
$48.5M
$441.1M
Q1 24
$51.0M
$415.3M
Total Assets
PBYI
PBYI
USLM
USLM
Q4 25
$216.3M
$681.0M
Q3 25
$202.9M
$652.8M
Q2 25
$194.9M
$607.4M
Q1 25
$196.2M
$585.3M
Q4 24
$213.3M
$543.2M
Q3 24
$220.7M
$521.8M
Q2 24
$205.0M
$484.2M
Q1 24
$214.1M
$464.0M
Debt / Equity
PBYI
PBYI
USLM
USLM
Q4 25
0.17×
0.00×
Q3 25
0.30×
0.00×
Q2 25
0.43×
0.00×
Q1 25
0.58×
0.00×
Q4 24
0.74×
0.00×
Q3 24
1.12×
0.00×
Q2 24
1.87×
0.00×
Q1 24
2.00×
0.00×

Cash Flow & Capital Efficiency

How much cash each business actually produces after reinvestment. Cash flow is harder to manipulate than net income.

Metric
PBYI
PBYI
USLM
USLM
Operating Cash FlowLast quarter
$14.4M
$45.6M
Free Cash FlowOCF − Capex
$14.4M
$25.7M
FCF MarginFCF / Revenue
19.1%
29.2%
Capex IntensityCapex / Revenue
0.0%
22.6%
Cash ConversionOCF / Net Profit
1.49×
TTM Free Cash FlowTrailing 4 quarters
$41.7M
$102.3M

8-quarter trend — quarters aligned by calendar period.

Operating Cash Flow
PBYI
PBYI
USLM
USLM
Q4 25
$14.4M
$45.6M
Q3 25
$9.7M
$45.9M
Q2 25
$14.1M
$34.0M
Q1 25
$3.6M
$39.4M
Q4 24
$15.6M
$38.6M
Q3 24
$11.0M
$39.0M
Q2 24
$1.0M
$21.2M
Q1 24
$11.2M
$27.2M
Free Cash Flow
PBYI
PBYI
USLM
USLM
Q4 25
$14.4M
$25.7M
Q3 25
$9.7M
$31.3M
Q2 25
$14.1M
$20.8M
Q1 25
$3.6M
$24.6M
Q4 24
$15.6M
$27.6M
Q3 24
$11.0M
$33.9M
Q2 24
$1.0M
$16.8M
Q1 24
$20.3M
FCF Margin
PBYI
PBYI
USLM
USLM
Q4 25
19.1%
29.2%
Q3 25
17.7%
30.7%
Q2 25
26.8%
22.7%
Q1 25
7.7%
26.9%
Q4 24
26.4%
34.4%
Q3 24
13.7%
37.9%
Q2 24
2.1%
21.9%
Q1 24
28.4%
Capex Intensity
PBYI
PBYI
USLM
USLM
Q4 25
0.0%
22.6%
Q3 25
0.0%
14.4%
Q2 25
0.0%
14.5%
Q1 25
0.1%
16.3%
Q4 24
0.0%
13.8%
Q3 24
0.0%
5.8%
Q2 24
0.0%
5.7%
Q1 24
0.0%
9.5%
Cash Conversion
PBYI
PBYI
USLM
USLM
Q4 25
1.49×
Q3 25
1.10×
1.18×
Q2 25
2.41×
1.10×
Q1 25
1.21×
1.16×
Q4 24
1.43×
Q3 24
0.54×
1.17×
Q2 24
0.81×
Q1 24
1.21×

Financial Flow Comparison

Revenue → gross profit → operating profit → net profit for each company.

Related Comparisons